- Home
- APLT vs VIGL Comparison
APLT vs VIGL Comparison
Compare APLT & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- VIGL
- Stock Information
- Founded
- APLT 2016
- VIGL 2020
- Country
- APLT United States
- VIGL United States
- Employees
- APLT N/A
- VIGL N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- VIGL Health Care
- Exchange
- APLT Nasdaq
- VIGL Nasdaq
- Market Cap
- APLT 80.3M
- VIGL 89.3M
- IPO Year
- APLT 2019
- VIGL 2022
- Fundamental
- Price
- APLT $0.53
- VIGL $3.03
- Analyst Decision
- APLT Buy
- VIGL Strong Buy
- Analyst Count
- APLT 7
- VIGL 5
- Target Price
- APLT $6.10
- VIGL $21.00
- AVG Volume (30 Days)
- APLT 3.0M
- VIGL 642.5K
- Earning Date
- APLT 03-05-2025
- VIGL 03-25-2025
- Dividend Yield
- APLT N/A
- VIGL N/A
- EPS Growth
- APLT N/A
- VIGL N/A
- EPS
- APLT N/A
- VIGL N/A
- Revenue
- APLT N/A
- VIGL N/A
- Revenue This Year
- APLT N/A
- VIGL N/A
- Revenue Next Year
- APLT $2,622.90
- VIGL N/A
- P/E Ratio
- APLT N/A
- VIGL N/A
- Revenue Growth
- APLT N/A
- VIGL N/A
- 52 Week Low
- APLT $0.53
- VIGL $1.49
- 52 Week High
- APLT $10.62
- VIGL $6.06
- Technical
- Relative Strength Index (RSI)
- APLT 29.75
- VIGL 77.87
- Support Level
- APLT $0.54
- VIGL $2.71
- Resistance Level
- APLT $0.70
- VIGL $2.95
- Average True Range (ATR)
- APLT 0.06
- VIGL 0.21
- MACD
- APLT 0.06
- VIGL 0.03
- Stochastic Oscillator
- APLT 0.00
- VIGL 86.18
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.